| Literature DB >> 30487245 |
Abolfazl Rad1,2, Umut Altunoglu3, Rebecca Miller4, Reza Maroofian5, Natalie Hauser4, Murat Gunel6, Hulya Kayserili3,7, Miriam Schmidts1,8, Kiely N James9, Ahmet Okay Çağlayan6,10, Maryam Najafi1, Valentina Stanley9, Rose-Mary Boustany11,12, Gözde Yeşil13, Afsaneh Sahebzamani14, Gülhan Ercan-Sencicek6, Kolsoum Saeidi15,16, Kaman Wu1, Peter Bauer17, Zeineb Bakey1,8, Joseph G Gleeson9.
Abstract
BACKGROUND: Putative nucleotidyltransferase MAB21L1 is a member of an evolutionarily well-conserved family of the male abnormal 21 (MAB21)-like proteins. Little is known about the biochemical function of the protein; however, prior studies have shown essential roles for several aspects of embryonic development including the eye, midbrain, neural tube and reproductive organs.Entities:
Keywords: zzm321990MAB21L1zzm321990; Cerebello-Oculo-Facio-genital (COFG) syndrome; corneal dystrophy; pontocerebellar hypoplasia; scrotal/labial aplasia
Mesh:
Substances:
Year: 2018 PMID: 30487245 PMCID: PMC6581149 DOI: 10.1136/jmedgenet-2018-105623
Source DB: PubMed Journal: J Med Genet ISSN: 0022-2593 Impact factor: 6.318
Figure 1Clinical phenotype of COFG individuals harbouring biallelic MAB21L1 loss of function variants. (A–L) Depicted craniofacial dysmorphism, medially sparse/flared and laterally extending eyebrows, synophrys, buphthalmos, anteverted nares, long and tented philtrum, flat nasal bridge, low anterior hairline and horizontal nystagmus with strabismus (A–D: individuals from family 1; E–H and Aa: individual 4_V:1 from 7 years of age to adulthood; I, J, Ab: individual 5_IV:1 from childhood to adulthood; K, L: individual 4_IV.4 from childhood to adulthood, M: individual 3_II.3). Widely spaced hypoplastic nipples with no noticeable areolae or hyperpigmentation and a tuft of terminal hair extruding from the lactiferous ducts (N: individual 1_VI:7; O: individual 4_V:1; P: 5_IV:4). Undescended testes, bilateral scrotal agenesis with normal median raphe in individual 1_VI:2 (Q), 4_V:1 (R), 5_IV:4 (S). Absence of labia majora and small labia minora in individuals 1_VI:5 (T) and 5_IV:1 (U). Corneal opacities in individual 1_VI:7 (V) and individual 5_IV:1. (V`). Cerebellar hypoplasia with absence/hypoplasia of the vermis in individuals 2_II:3 (W, X), 4_V:1 (Z, I_IV.V). Optic atrophy in individual 2_II:3 (Y). COFG, Cerebello-Oculo-Facio-Genital.
Clinical findings in individuals harbouring biallelic MAB21L1 variants
| Family 1 | Family 2 | Family 3 | Family 4* | Family 5* | Family 6† | ||||||
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patent 5 | Patient 6 | Patient 7 | Patient 8 | Patient 9 | Patient 10 | Patient 11 | |
| MAB21L1 mutation | c.841delG, p.Glut281fs*20 | c.698 A>C, p.Gln233Pro | c.279_286delACTGCCCG (p.Ser93Serfs*48) | c.859delC, p.Arg287Glufs*14 | c.840C>G; p.Tyr280* | c.735dupG, p.Cys246Leufs*18 | |||||
| Ancestry | Persian | Persian | Lebanese Shia | Turkish | Turkish | Algerian | |||||
| Sex | Female | Female | Male | Male | Male | Female | Male | Female | Male | Female | Male |
| Consanguinity | 1° cousins | 1° cousins | 1° cousins | 2° cousins | 1° cousins | 1° cousins | |||||
| Growth parameters | |||||||||||
| Measurements at birth (SD) | 3.5 kg (0.81), n/a, | 3.1 kg (−0.62), n/a, 34 cm (−0.54) | 3.1 kg (−0.74), | n/a | 3.6 kg (+0.08), 56 cm (+2.23), 34 cm (−0.54) | 2.8 kg (−1.19), 49 cm (−0.20), | 3.45 kg (−0.18), 50 cm (−0.06), | n/a | 3.5 kg (−0.10), n/a, n/a | n/a | n/a, n/a, n/a |
| Age at last evaluation | 7 years | 5 years | 7 months | 17 years | 26 months | 2 years | 18 years 9 months | 16 years | 10 years 6 months | 12 months | 7 years |
| Height (SD) | 119 cm (−0.47) | 106 cm (−0.36) | 67 cm (−0.62) | 157 cm (2.10) | n/a | 87.5 cm (+0.36) | 170 cm (−0.92) | 165 cm (+0.43) | 130 cm (−1.57) | n/a | 116 cm (−1.7) |
| Weight (SD) | 18 kg (−1.75) | 14 kg (−2.02) | 7 kg (−1.57) | 47 kg (−1.91) | n/a | 11.1 kg (−0.96) | 74 kg (+0.31) | 50 kg (−0.50) | 38 kg (+0.48) | n/a | 20 kg (−1.18) |
| OFC (SD) | 49 cm (−1.96) | 52 cm (+1.19) | 41 cm (−2.47) | 55.5 cm (−0.07) | n/a | 47.5 cm (+0.02) | 52 cm (−2.09) | 46 cm (−6.86) | 45.8 cm (−5.52) | 41.5 cm (−3.20) | 50 cm (−1.50) |
| Craniofacial findings | |||||||||||
| Short forehead | + | + | + | + | + | + | + | + | + | + | + |
| Medially sparse/flared and laterally extended eyebrows | + | + | + | + | + | +- | + | + | + | + | + |
| Low-set ears | – | – | – | – | – | + | + | – | n/a | + | |
| Ocular abnormalities | |||||||||||
| Horizontal nystagmus | + | + | + | in infancy | + | – | + | + | + | + | + |
| Bilateral corneal opacities/corneal dystrophy | + | + | + | + | + | + | + | + | + | + | + |
| Genitourinary findings/breasts | |||||||||||
| Absent scrotum/labia majora | + | + | + | + | + | + | + | + | + | + | + |
| Hypospadias | NA | NA | – | – | + | NA | - | NA | + | NA | - |
| Tuft of hair extruding from the lactiferous ducts | – | – | – | + | n/a | n/a | + | + | + | + | +‡¥ |
| Neurological features | |||||||||||
| Global DD/ID | Severe | Severe | n/a | Moderate | n/a | Severe | Moderate to severe | Moderate | Moderate | Severe | Severe |
| Cranial MRI findings | Cerebellar hypoplasia, | n/a | n/a | Cerebellar hypoplasia, | Cerebellovermian hypoplasia, optic nerve hypoplasia | Cerebellovermian hypoplasia with pontine involvement | Severe cerebellar and vermian hypoplasia and large parietal cyst | Cerebellovermian hypoplasia with pontine involvement | Cerebellovermian hypoplasia with pontine involvement | Cerebellovermian hypoplasia with pontine involvement | Dandy-Walker malformation |
| Endocrinological evaluation | |||||||||||
| Basal testosterone | NA | NA | n/a | n/a | Normal | NA | 3.20 ng/mL (2.7–10.7) | NA | 0.02 ng/mL (0.07–0.2) | NA | Normal |
| Basal estradiol | n/a | n/a | NA | NA | NA | n/a | NA | 68.55 pg/mL (0–266) | NA | n/a | NA |
| Response to short stimulation test | NA | NA | n/a | n/a | n/a | NA | Adequate | NA | Adequate | NA | n/a |
| LH, FSH | n/a | n/a | n/a | n/a | n/a | n/a | 4.6 mIU/mL (1.7–8.6) | 6.13 mIU/mL (1.6–8.3) | 0.03 mIU/mL (0.3–2.8) | n/a | Normal |
| Other | |||||||||||
| – | – | – | Heart murmur | Retinal degeneration | Decreased sensitivity to pain | – | – | – | – | ||
*Patients’ phenotypes previously published.13
†Patient phenotype and causative MAB21L1 mutation previously published.12
‡Personal communication with J. Thevenon.
DD, developmental delay; FSH, follicle stimulating hormone; ID, intellectual disability; LH, luteinising hormone; n/a, not available; NA, not applicable; +, present; –, absent.
Figure 2Pedigrees, MAB21L1 mutation segregation patterns and mutation localisation on cDNA and protein level. (A) Pedigrees of four families harbouring biallelic MAB21L1 loss-of function variants identified by ES. In total, nine affected individuals were identified. Wildtype alleles are indicated by ‘+’, alleles carrying identified variants with ‘ -’. (B) Visualisation of the MAB21L1 gene and COFG associated alleles identified by us as well as the previously identified MAB21L1 allele Bruel et al.12 (C) Schematic overview of localisations of COFG alleles on protein level. (D) Computational structural model of human MAB21L1, Visualisation of the aminoacid change identified in family 2 and predicted effect on protein folding/structure and evolutionary conservation of the mutated position among species. The variant is predicted to disrupt hydrogen bond formation within the alpha-helix structure, disrupting the protein secondary structure. COFG, Cerebello-Oculo-Facio-Genital; ES, exomic sequencing.